Home Tags Sanofi

Tag: Sanofi

Seeking a cure: Regeneron and NYMC in COVID-19 study

When a complex process that normally takes seven to nine months is accomplished in only eight days, you can be reasonably certain that something...

Regeneron moves forward with two drugs against COVID-19

Regeneron has started a drug trial to see whether the drug Kevzara that it developed with the French multinational pharmaceutical company Sanofi and has...

Regeneron, Sanofi restructure Kevzara, Praluent collaboration

Under the new agreement, Paris-based Sanofi would gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent, while Tarrytown’s Regeneron would gain sole U.S. rights to Praluent.

Boehringer Ingelheim, Sanofi targeted in class-action suit over Zantac

According to the lawsuit, “Zantac’s unprecedented sales were possible only because of a deception perpetrated by the drug’s manufacturers on consumers.”

Federal court rules in favor of Regeneron in Praluent patent lawsuit

Judge Richard Andrews’ Aug. 28 ruling overturned portions of a jury verdict in February that found Amgen’s patents on its cholesterol drug Repatha were valid. Regeneron and Sanofi sell rival drug Praluent.

Regeneron moves closer to European approval of drug for asthma

In the U.S., it is indicated for use by prescription to treat moderate-to-severe atopic dermatitis, also known as eczema.

FDA approves Regeneron, Sanofi skin cancer immuno-oncology drug

The drug is the first FDA-approved treatment for patients with advanced forms of a skin cancer known as cutaneous squamous cell carcinoma. 

FDA to review Regeneron’s cemiplimab for treatment of squamous cell carcinoma

These cancers commonly appear on sun-exposed areas of the body such as the face, ears, neck, lips and backs of the hands.

European agency to review Regeneron-Sanofi drug applications

The European agency will also review the marketing authorization application for cemiplimab, which is used to treat patients with metastatic cutaneous squamous cell carcinoma.

Regeneron dermatitis drug Dupixent approved in Japan

The antibody drug was approved for use in the U,S. last March.

Regeneron, Sanofi increase investment in drug developments

The companies will increase their investments in the development of cancer drug cemiplimab and food allergy drug dupilumab.

Regeneron, Sanofi announce positive results for food allergy drug

Dupilumab showed positive results in adults with eosinophilic esophagitis, an allergic inflammatory disease that damages the esophagus.

Regeneron dermatitis drug approved for European market

The antibody drug will be marketed as Dupixent and available to adults with moderate to severe atopic dermatitis .

Regeneron drug for rheumatoid arthritis approved in Europe

The European Commission approved the use of Kevzara under certain conditions to treat adults with moderately to severely active rheumatoid arthritis.

FDA approves Regeneron drug Kevzara for rheumatoid arthritis

The new human antibody drug will be used to treat a chronic inflammatory disease that affects about 1.3 million Americans.